{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "regularMarketChangePercent": 2.8046603, "regularMarketPrice": 37.8425, "exchange": "PNK", "shortName": "ZEALAND PHARMA AS", "longName": "Zealand Pharma A/S", "messageBoardId": "finmb_1268514", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "firstTradeDateMilliseconds": 1361802600000, "priceHint": 2, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -3.49, "epsForward": -1.49, "sharesOutstanding": 58351900, "bookValue": 15.852, "fiftyDayAverage": 32.927353, "fiftyDayAverageChange": 4.915146, "fiftyDayAverageChangePercent": 0.14927243, "twoHundredDayAverage": 27.075266, "twoHundredDayAverageChange": 10.767233, "twoHundredDayAverageChangePercent": 0.39767784, "marketCap": 2208181760, "forwardPE": -25.39765, "priceToBook": 2.387238, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.0 - Strong Buy", "tradeable": false, "cryptoTradeable": false, "regularMarketChange": 1.0323982, "regularMarketTime": 1684164892, "regularMarketDayHigh": 38.0, "regularMarketDayRange": "37.8425 - 38.0", "regularMarketDayLow": 37.8425, "regularMarketVolume": 680, "regularMarketPreviousClose": 36.8101, "fullExchangeName": "Other OTC", "financialCurrency": "DKK", "regularMarketOpen": 38.0, "averageDailyVolume3Month": 164, "averageDailyVolume10Day": 674, "fiftyTwoWeekLowChange": 26.7025, "fiftyTwoWeekLowChangePercent": 2.3969927, "fiftyTwoWeekRange": "11.14 - 38.0", "fiftyTwoWeekHighChange": -0.15750122, "fiftyTwoWeekHighChangePercent": -0.004144769, "fiftyTwoWeekLow": 11.14, "fiftyTwoWeekHigh": 38.0, "symbol": "ZLDPF"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Sydmarken 11", "address2": "SOeborg", "city": "Copenhagen", "zip": "2860", "country": "Denmark", "phone": "45 88 77 36 00", "fax": "45 88 77 38 98", "website": "https://www.zealandpharma.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing both insulin and dasiglucagon. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.", "fullTimeEmployees": 196, "companyOfficers": [{"maxAge": 1, "name": "Mr. Adam Sinding Steensberg M.D.", "age": 48, "title": "Pres & CEO", "yearBorn": 1974, "fiscalYear": 2021, "totalPay": {"raw": 749772, "fmt": "749.77k", "longFmt": "749,772"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Henriette  Wennicke", "age": 39, "title": "EVP & CFO", "yearBorn": 1983, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ivan Mourits Moller", "age": 50, "title": "Exec. VP & COO", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Mads  Kronborg", "title": "Head of Investor Relations & Communication", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Ravinder  Chahil", "age": 54, "title": "Sr. VP & Gen. Counsel", "yearBorn": 1968, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Christina Sonnenborg Bredal", "age": 37, "title": "Sr. VP and Global Head of People & Organization", "yearBorn": 1985, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Jens Damsgaard Mikkelsen M.D.", "title": "Head of Molecular Pharmacology", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Danilo  Verge", "title": "Head of Global Medical Affairs", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. David M. Kendall M.D.", "age": 61, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1961, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Lykke  Romer", "title": "VP & Head of Fin. and Accounting", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 4, "boardRisk": 1, "compensationRisk": 9, "shareHolderRightsRisk": 1, "overallRisk": 4, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}